MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318205 | Name: Methyclothiazide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Methyclothiazide is a thiazide diuretic with properties similar to those of Hydrochlorothiazide.

Chemical Structure

Methyclothiazide
Methyclothiazide
CAS# 135-07-9

Theoretical Analysis

MedKoo Cat#: 318205

Name: Methyclothiazide

CAS#: 135-07-9

Chemical Formula: C9H11Cl2N3O4S2

Exact Mass: 358.9568

Molecular Weight: 360.22

Elemental Analysis: C, 30.01; H, 3.08; Cl, 19.68; N, 11.66; O, 17.77; S, 17.80

Price and Availability

Size Price Availability Quantity
10mg USD 250.00 2 weeks
25mg USD 450.00 2 weeks
50mg USD 800.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Methyclothiazide; Aquatensen; Duretic; Enduron; Methyclothiazid; Enduronum; AB0012760; FT-0654252; A806880; S4057,135-07-9;
IUPAC/Chemical Name
6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
InChi Key
CESYKOGBSMNBPD-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)
SMILES Code
CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Methyclothiazide is an orally active antihypertensive agent and a diuretic agent.
In vitro activity:
TBD
In vivo activity:
Methyclothiazide (MCTZ), a thiazide diuretic, inhibits the contractile response induced by norepinephrine in aortic rings from 12-week-old spontaneously hypertensive rats (SHR). These results suggest that the MCTZ effects on the norepinephrine-evoked vascular response are mediated by an endothelium-dependent mechanism involving endothelium-dependent relaxing factor (EDRF)/nitric oxide (NO) release. Reference: Eur J Pharmacol. 2000 Nov 10;408(1):63-7. https://pubmed.ncbi.nlm.nih.gov/11070184/
Solvent mg/mL mM comments
Solubility
DMSO 72.0 199.88
Ethanol 4.0 11.10
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 360.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Colas B, Slama M, Collin T, Safar M, Andrejak M. Mechanisms of methyclothiazide-induced inhibition of contractile responses in rat aorta. Eur J Pharmacol. 2000 Nov 10;408(1):63-7. doi: 10.1016/s0014-2999(00)00704-4. PMID: 11070184. 2. Sasaki S, Takeda K, Takahashi H, Yoneda S, Okajima H, Iyoda I, Yoshimura M, Ijichi H. KCl inhibits hypothalamic activity to attenuate hypertension in DOCA-salt rats. Jpn Circ J. 1984 Nov;48(11):1251-9. doi: 10.1253/jcj.48.1251. PMID: 6502916.
In vitro protocol:
TBD
In vivo protocol:
1. Colas B, Slama M, Collin T, Safar M, Andrejak M. Mechanisms of methyclothiazide-induced inhibition of contractile responses in rat aorta. Eur J Pharmacol. 2000 Nov 10;408(1):63-7. doi: 10.1016/s0014-2999(00)00704-4. PMID: 11070184. 2. Sasaki S, Takeda K, Takahashi H, Yoneda S, Okajima H, Iyoda I, Yoshimura M, Ijichi H. KCl inhibits hypothalamic activity to attenuate hypertension in DOCA-salt rats. Jpn Circ J. 1984 Nov;48(11):1251-9. doi: 10.1253/jcj.48.1251. PMID: 6502916.
1: Shimizu H, Nagami S, Takahashi N. [A case of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in which lomerizine hydrochloride was suggested to prevent recurrent stroke]. Rinsho Shinkeigaku. 2014;54(1):22-6. Japanese. PubMed PMID: 24429644. 2: Soghikian K, Bartenbach DE. Influence of dosage and duration of therapy on the rate of response to methyclothiazide in essential hypertension. South Med J. 1977 Dec;70(12):1397-404. PubMed PMID: 594788. 3: Spireas S, Wang T, Grover R. Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. Drug Dev Ind Pharm. 1999 Feb;25(2):163-8. PubMed PMID: 10065349. 4: Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC. The effects of terazosin and methyclothiazide on blood pressure and serum lipids. Am Heart J. 1989 Apr;117(4):842-7. PubMed PMID: 2564723. 5: Desaulles E, Schwartz J. A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin. Br J Pharmacol. 1979 Feb;65(2):193-6. PubMed PMID: 760897; PubMed Central PMCID: PMC1668622. 6: Black HR, Chrysant SG, Curry CL, Frishman WH, Grimm RH, Lasseter KC, Okun R, Pool JL, Raizada V, Vlachakis ND, et al. Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. J Clin Pharmacol. 1992 Apr;32(4):351-9. PubMed PMID: 1349028. 7: Gordon RD, Mortimer RH, Saar N. Failure of methyclothiazide to lower home blood pressure level in "essential" hypertensive and normotensive young men, despite significant plasma volume contraction. Eur J Clin Pharmacol. 1977 Dec 28;12(6):403-8. PubMed PMID: 598414. 8: Colas B, Slama M, Masson H, Colas JL, Collin T, Arnould ML, Hary L, Safar M, Andrejak M. Direct vascular actions of methyclothiazide and indapamide in aorta of spontaneously hypertensive rats. Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):363-8. PubMed PMID: 11030443. 9: Sasaki S, Buñag RD. Methyclothiazide attenuates salt-induced hypertension without affecting sympathetic responsiveness in Dahl rats. J Cardiovasc Pharmacol. 1983 May-Jun;5(3):378-83. PubMed PMID: 6191135. 10: Methyclothiazide in hypertension. A report from the General Practitioner Research Group. Practitioner. 1978 Jun;220(1320):969-71. PubMed PMID: 683938. 11: ABRUZZI WA. PROLONGED METHYCLOTHIAZIDE-DESERPIDINE THERAPY IN HYPERTENSIVE YOUNG ADULTS. N Y State J Med. 1965 Aug 15;65:2146-8. PubMed PMID: 14335191. 12: SAMBHI MP, VENNING EH, BECK JC. ALDOSTERONE SECRETION RATE AND ELECTROLYTE BALANCE STUDIES ON THREE PATIENTS WITH HYPERTENSION. INFLUENCE OF GUANETHIDINE, HYDRALAZINE AND METHYCLOTHIAZIDE. Metabolism. 1964 Mar;13:212-20. PubMed PMID: 14127688. 13: TOKUDA A, HOTTA M, OKAMOTO N, TAKEDA C, ISOBE T, YASUI S. [CLINIC TRIAL OF METHYCLOTHIAZIDE (ENDURON)]. Chiryo. 1963;45:2271-5. Japanese. PubMed PMID: 14103597. 14: GOTO Y, KODAMA R, TAKIZUKA H, MURAKAMI E, NAGANO S, NAKAMURA H, KAKIMI A, KATO M. [ON THE HYPOTENSIVE EFFECTIVENESS OF METHYCLOTHIAZIDE]. Chiryo. 1963;45:2188-94. Japanese. PubMed PMID: 14103583. 15: BARRERAARENAS F. [CLINICAL TRIAL WITH THE COMBINATION OF PARGYLINE AND METHYCLOTHIAZIDE IN THE TREATMENT OF ESSENTIAL ARTERIAL HYPERTENSION]. Medicina (Mex). 1965 Mar 10;45:110-5. Spanish. PubMed PMID: 14346210. 16: POLLACK PJ. PARGYLINE HYDROCHLORIDE AND METHYCLOTHIAZIDE COMBINED IN THE TREATMENT OF HYPERTENSION. Curr Ther Res Clin Exp. 1965 Jan;7:10-8. PubMed PMID: 14246362. 17: PATEL N, MOCK DC Jr, COLMORE JP, CLARK M. A COMPARATIVE CLINICAL STUDY OF METHYCLOTHIAZIDE AND PARGYLINE IN PATIENTS WITH ESSENTIAL HYPERTENSION. Clin Pharmacol Ther. 1963 Nov-Dec;4:740-8. PubMed PMID: 14085302. 18: TALSO PJ, CARBALLO AJ. METHYCLOTHIAZIDE IN THE MANAGEMENT OF HYPERTENSIVE DISEASE. Curr Ther Res Clin Exp. 1963 Aug;5:401-6. PubMed PMID: 14057775. 19: Colas B, Collin T, Safraou F, Chatelain D, Cordonnier C, Henry X, Safar M, Andrejak M, Slama M. Direct vascular actions of methyclothiazide in remodeled mesenteric arteries from hypertensive patients. Am J Hypertens. 2001 Oct;14(10):989-94. PubMed PMID: 11710791. 20: Flensted-Jensen E. [Methyclothiazide in the therapy of patients with heart insufficiency]. Ugeskr Laeger. 1968 Feb 15;130(7):278-81. Danish. PubMed PMID: 5676614.